OTTAWA, ONTARIO–(Nov. 3, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP“), is pleased to announce that it has signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR“) licensed producer Aphria Inc. (“Aphria“) (TSX VENTURE:APH)(OTCQB:APHQF) for the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001. PPP001 is a medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe.
Aphria is a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations.Under this supply agreement with Aphria, PPP shall pursue the development of a prescription controlled inhalation drug product of medical marijuana and seek marketing approval across the world either directly or indirectly through partnerships or licensing agreements. Aphria will be the exclusive supplier of this API to PPP for the development and commercialisation of PP001.
PPP is granted an exclusive, non-transferrable, royalty free, licence to use the API in the development of PPP001. The agreement defines a purchase price during the clinical development and a volume rebate once a target volume is reached.
Both Canadian and USA prescription drug regulations impose rigorous quality systems for the manufacturing of both the API and finished drug product. These requirements include conformance to pharmaceutical Good Manufacturing Practice regulations (“GMP“) as well as demonstrating the ability of the manufacturer to ensure lot-to-lot consistency in the quality and safety of the prescription drug.
Dr. Guy Chamberland, M.Sc., Ph.D., Chief Scientific Officer and Regulatory Affairs, PhytoPain Pharma Inc., commented, “We are very pleased and excited to be working with Aphria in the development of PPP001. Developing prescription botanical based pharmaceuticals requires a high quality GMP system and well-established product specifications to ensure consistent efficacy and ultimately protect the safety of patients. Based on our assessment of Aphria, we are confident that their high quality GMP medical cannabis production facility and impressive quality assurance team will meet or exceed the expectations of both the Canadian and USA prescription drug authorities.”
“With this agreement in place, PPP is now in a solid position to submit its Clinical Trial Application (CTA) for its planned Phase I trial in healthy volunteers. The company is also on track for submitting its Pre-IND Information Package for its upcoming meeting the US FDA,” stated Dr. Chamberland.
“Aphria is excited and proud to be an integral part of advancing the scientific research being led by Dr. Chamberland and the team at Tetra Bio-Pharma. Using our proprietary and high quality medical cannabis blend supported by high calibre research is exactly what professional healthcare practitioners require to gain the confidence to prescribe medical cannabis as a pharmaceutical,” said Vic Neufeld, Chief Executive Officer, Aphria Inc.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Neither the TSX Venture Exchange (the “Exchange”) nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
André Rancourt
Chief Executive Officer
Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications
Tetra Bio-Pharma Inc.
André Audet
Executive Chairman
(613) 421-8402
Aphria Inc.
Vic Neufeld
1-844-427-4742
OTTAWA, ONTARIO–(Nov. 2, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP“), is pleased to announce that it held its Scientific and Clinical Advisory Board (“CAB“) meeting on October 29th. The CAB reviewed the development program of PPP’s inhalation cannabis product PPP001. PPP001 is a medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe.
The Board, which is comprised of experts in clinical research, pain management as well as cancer, and neurological product drug development (ref: news release August 26, 2016), met to review and discuss the development program to date, the study design of the Phase I trial and the overall clinical development plan of PPP001. This included the exclusion and inclusion criteria of the proposed Phase I trial, the Phase 1a and 1b dosing scheme, and the pharmacokinetic and pharmacodynamic assessments. The CAB also examined the clinical rationale for the selection of the delta-9-tetrahydrocannibinol (THC) and Cannabidiol (CBD) dose levels for use in PPP001.
The CAB also reviewed the salient elements of future PPP’s Phase II and III clinical trials for the development of PPP001 in various medical conditions, including the use of medical marijuana as a second or third line therapy for cancer and HIV patients with uncontrolled pain. The CAB reports directly to the Board of Directors of the Company and will be submitting a report on the outcome of the CAB meeting in the near future.
Currently, there is only limited safety or efficacy information, if any, derived from well-controlled clinical trials available to physicians to adequately assess the benefits and risks of prescribing medical marijuana. Dr. Luc Vachon, President of the CAB commented: ²the members of the CAB are very pleased and excited to be participating in a full pharmaceutical approach on the development of medical marijuana as a prescription drug. The members expressed that the clinical development plan used by PPP – supported by a formal regulatory path – will help generate the type of clinical information required by physicians.²
“This team of scientific and clinical experts provided us with excellent guidance on the development program. We are pleased to recommend to the Board of Directors that PPP is ready to submit the Clinical Trial Application (CTA) for the conduct of its Phase I trial in healthy human volunteers,” stated Dr. Chamberland, Chief Scientific Officer and Regulatory Affairs.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
André Rancourt
Chief Executive Officer
(613) 421-8402
Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications
(613) 421-8402
Tetra Bio-Pharma Inc.
André Audet
Executive Chairman
(613) 421-8402
OTTAWA, ONTARIO–(Oct. 26, 2016) – Tetra Bio-Pharma Inc. (“Tetra Bio” or the “Company“) (CSE:TBP)(CSE:TBP.CN), through its subsidiary, Agro-Tek Inc. (“AGTK“), is pleased to announce that it has acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa.
The recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content. According to the United States Food and Drug Administration (“FDA“), “FDA is not aware of any evidence that would call into question its current conclusion that cannabidiol products are excluded from the dietary supplement definition under section 201(f)(3)(B)(ii) of the Federal Food, Drug, & Cosmetics Act.”
Mr. André Rancourt, the Company’s CEO commented, “CBD or THC containing dietary supplements are currently not allowed on the USA market. However, the goal of the McGill University partnership is the development of extracts of the plant Cannabis sativa, including THC and CBD-free for the development of dietary supplements.” AGTK intends on manufacturing and commercializing supplements, food-type products and, natural health products that are compliant with Canadian and USA federal regulations. Mr. Rancourt added, “This commercial strategy involves the expertise of two of the Company’s subsidiaries, AGTK and MMP, and is in line with the Company’s vision to make AGTK and MMP leaders in the development of Cannabis sativa, derived products for the consumer market, and for the commercialization of natural supplements derived from Cannabis sativa.”
The assets acquired include proprietary formulations that have obtained marketing approval from Health Canada. The line consists of:
1. Glucose Aid; NPN 80058089
2. Kava Kava; NPN 80061986
3. Stress Ado; NPN 80065911
4. Toux Ado (Cough Ado); NPN 80065923
5. Toux enfant (Cough Children); NPN 80065928
6. Water Relax; NPN 80065948 (beverage supplement)
7. Water Cough; NPN 80066086 (beverage supplement)
8. Sleep Pro; NPN 80066679
9. Instant Relief; NPN 80066682 (topical gel for local pain relief).
The acquisition of these formulations and their proprietary ingredients will provide PhytoPain Pharma Inc. with an inventory of compounds and elements that will be used as secondary ingredients or catalysts in the formulation of our pharmaceutical grade products.
In consideration for the acquisition of the assets, the Company has issued 1,800,000 common shares to arms’ length individuals. The shares issued will be subject to a four-month hold period.
According to Mr. Rancourt, these products will allow AGTK to begin generating revenues. This is the first set of products for AGTK’s portfolio. The company will be seeking to acquire additional product lines for distribution in North America. AGTK is engaged in negotiations to acquire national distributors to expand brand identity and facilitate distribution across North America
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
Ryan Brown
VP Business Development and Communications
Andre Audet
Executive Chairman
(613) 421-8402
[email protected]
OTTAWA, ONTARIO–(Oct. 24, 2016) – Tetra Bio-Pharma Inc. (“Tetra Bio” or “the Company”) (CSE:TBP)(CSE:TBP.UN) is increasing its $750,000 non-brokered private placement (ref.: news release of October 20, 2016) to $1,000,000 for up to 6,666,667 units at a price of $0.15 per unit. Each unit will be consisting of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.20 for a period of 12 months following the closing date.
The private placement is expected to close no later than November 30, 2016.
The securities issued pursuant to the private placement will be subject to a four-month hold period from the closing date. The Company may pay a commission in connection with the private placement, subject to compliance with the policies of the Exchange. Completion of the private placement and the payment of any commissions remain subject to the receipt of all necessary regulatory approvals, including the approval of the Exchange.
The proceeds of the private placement will be used to initiate clinical trials.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Andre Rancourt
Chief Executive Officer
Ryan Brown
VP Business Development and Communications
André Audet
Executive Chairman
[email protected]
(613) 421-8402
OTTAWA, ONTARIO–(Oct. 20, 2016) – Tetra Bio-Pharma Inc. (“Tetra Bio” or “the Company”) (CSE:TBP)(CSE:TBP.CN) is conducting a non-brokered private placement of up to 5,000,000 units at a price of $0.15 per unit for aggregate gross proceeds of up to $750,000. Each unit will consist of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.20 for a period of 12 months following the closing date.
The private placement is expected to close no later than November 30, 2016.
The securities issued pursuant to the private placement will be subject to a four-month hold period from the closing date. The Company may pay a commission in connection with the private placement, subject to compliance with the policies of the Exchange. Completion of the private placement and the payment of any commissions remain subject to the receipt of all necessary regulatory approvals, including the approval of the Exchange.
The proceeds of the private placement will be used to initiate clinical trials.
In other News:
The Company has received $341,783 in exercised warrants from September to October 2016.
The Company also announces that in accordance with the Company’s stock option plan and subject to the approval of the Canadian Securities Exchange, the Board of Directors granted an aggregate of 800,000 incentive stock options (“options”) to directors of the Company. Each option, vesting immediately upon grant, entitles the holder thereof to purchase one common share in the capital of the Company at a price of $0.18 per share until October 19, 2021. The options and any common shares issued upon exercise thereof will be subject to a four month resale restriction from the date of grant.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 421-8402
Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications
(613) 421-8402
Tetra Bio-Pharma Inc.
Andre Audet
Executive Chairman
(613) 421-8402
[email protected]
OTTAWA, ONTARIO–(Oct. 19, 2016) – Grow Pros MMP Inc. (MMP), a subsidiary of Tetra Bio-Pharma Inc. (“TetraBio” or the “Company” or “TBP“) (CSE:TBP) is pleased to announce that the National Sciences and Engineering Research Council of Canada (NSERC) has awarded an NSERC Engage Grant partnership to MMP and Dr. Stan Kubow of McGill University.
As part of MMP’s mission to diversify and offer new products to consumers, with the award of the NSERC Engage partnership grant, MMP will establish a first research collaboration with McGill University and plans to invest in this program both financially and with in-kind contributions to pursue its research and development objectives and become a world leader in the development and commercialization of Cannabis-based products.
“The partnership with McGill University is in line with MMP’s vision to expand commercial operations and prepare to launch Cannabis sativa-derived supplement/retail or drug products for the North American market. This project will allow the development of intellectual property to protect future products that would be commercialized by TBP,” commented Ryan Brown.
“The proposed collaboration between Dr S. Kubow, Associate Professor, McGill University, relates to MMP’s need to develop an extraction process and to develop products using specific fractions of the plant Cannabis sativa. Fractions with the highest dermal and oral absorption will subsequently be characterized to further understand the pharmacology of these extracts,” commented Dr. Randy Ringuette, Ph.D. Medical Researcher, MMP Inc.
Dr. Stan Kubow stated, “We are excited by the collaboration with MMP that will allow us to utilize systematic state-of-the-art research methodologies to identify bioactives from Cannabis sativa for the development of science-based consumer products.”
According to Mr. A. Rancourt CEO of TBP, “We are very pleased by the decision of NSERC to award this partnership grant. This has implications for both MMP and AgroTek.” He added, “This is in line with TBP’s vision to make MMP a leader in the development of Cannabis sativa derived products for the consumer market and for the commercialization of natural supplements derived from Cannabis sativa by AgroTek.”
About Dr. Stan Kubow
Dr. S. Kubow, Ph.D. is an Associate Professor at the School of Dietetics and Human Nutrition, McGill University. His research interests include the impact of nutritional interventions on a variety of disease outcomes and metabolic disorders using technologically modified food extracts and isolates with enhanced bioactivity including phytochemical extracts, whey and soy proteins and probiotics. These studies have been focused upon oxidative stress, inflammatory indices, lipoprotein, fatty acid and glucose metabolism as related to cell signaling pathways and disease pathogenesis.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications
Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 421-8402
[email protected]
BONSALL, CA–(Marketwired – Oct 18, 2016) –
MARIJUANA COMPANY OF AMERICA INC., (“MCOA” or the “Company”) (OTC PINK:MCOA), an innovative cannabis and hemp marketing and distribution company, is providing this update to keep our shareholders and prospective investors informed.
Our first product, hempSMART BRAIN, formulated with CBD or Cannabidiol as the core ingredient combined with high quality, clinically proven, branded ingredients to compliment the CBD to support brain health. There are new articles published daily regarding the benefits of CBD, hempSMART BRAIN was formulated to meet the growing demand for cannabinoid based neutraceutical products that assist in brain function.
The hempSMART Brain product is scheduled for release by the end of October. It was expected to ship by the second week of October, but delays in receiving key ingredients from suppliers has pushed back the ship date by approximately two weeks. Our fulfillment center is ready to manage distribution of orders and they are working very closely with hempSMART’s manufacturer, which will result in significant efficiencies of scale.
hempSMART Brain is a first-of-its-kind product. The synergistic blend of clinically verified natural brain support ingredients, blended with water soluble CBD, enables crossing of the blood-brain barrier to provide optimal brain support and protection.
hempSMART Brain was developed to address the increase in neurologic and neurodegenerative challenges that have prompted a surge in scientific research on prevention and/or reversal of brain and nervous system pathology. A variety of natural products have been shown, in clinical trials, to improve neurological and cognitive function and there has been a surge of products being marketed to improve brain function.
Marketing leaders are currently preparing for the Brain product roll-out. The hempSMART prelaunch website: hempSMART.com is now active and accessible to the Company’s members.
According to the Direct Selling Association, in 2015 over 20 million people in the U.S. were involved in direct selling, with total sales of $36.1 billion. More than 74 percent of the American public has purchased goods or services through direct selling. Worldwide sales are also strong with more than $154 billion in sales. This marketing and distribution method is incredibly effective at creating solid sales and loyal members, as well as brand awareness in the marketplace because the sales “force” are people that passionately believe in the company, product and the difference it can make in people’s lives. The energy they can invest into the education of potential customers is far more than any other sales model.
Another key driver in the affiliate marketing industry is compensation or commission that is based on performance. Affiliate leaders earn rewards and compensation for developing training systems for their personal sales “teams” within hempSMART. Based on this win-win business model, companies can grow rapidly due to the success of the customer, the affiliate and the entire direct sales process.
Over the years, thousands of affiliate marketing teams have been established to promote new products for launch. Our affiliate marketing leaders are well established, long-term professionals. They are testing the system as well as preparing their marketing organizations for the Brain product launch. The Company has a robust affiliate marketing program that is integrated into the hempSMART.com full website which was designed and developed by ApogeeINVENT. This user-friendly platform will help our affiliates track their commissions and provide resources, and helpful information for marketing the Company’s products.
“We have received significant interest in this product and we are looking forward to updating the financial markets and our shareholders as the product release takes place,” said CEO, Donald Steinberg.
The Club Harmoneous pilot program has been extended due to regulatory challenges under the current non-profit regulatory model in California. The Company will continue to work through these challenges to develop a unique operating model that can operate under the current regulatory framework as well as the upcoming licensing and regulatory structure proposed by the Medical Marijuana Regulation and Safety Act (MMRSA). The Company is also prepared for the passing of Prop 64 in November for the adult use of marijuana in California. The Company continues to work closely with Green Dot Collective in Los Angeles County to overcome some of the regulatory challenges and changes in California. Upon satisfactory completion of the Southern California pilot program, the Company will begin expansion to Northern California and other legal adult use and medical marijuana states.
Investors are invited to visit the MCOA IR Hub on Agoracom to post questions and receive answers, or review questions and answers already posted by fellow investors. In addition, the MCOA IR HUB provides a monitored forum for investors and prospective shareholders to communicate within a clean, professional environment.
On behalf of the Board of Directors,
“Donald Steinberg”
Donald Steinberg
President & CEO
888-777-4362
MarijuanaCompanyofAmerica.com
About Marijuana Company of America, Inc.,
Marijuana Company of America (“MCOA”) is a publicly traded company headquartered in Southern California. MCOA will distribute marijuana and products related to marijuana as well as CBD and hemp, using a variety of marketing approaches to distribute on a global basis.
About hempSMART
The hempSMART brand represents MCOA’s non-THC, hemp derived, product line. All hempSMART products are formulated with a cannabinoid base that is derived from hemp and has less than a .3% THC content.
About Club Harmoneous
Club Harmoneous (The Club) delivers all of the benefits of cannabis to its members harmoneously. The Club provides a wide range of cannabis products to its members, medicinal, adult use or healthy foods, body care and cosmetics. The Club products are top-quality and offered to members at competitive prices with the convenience of home delivery.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Marijuana Company of America, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
Marijuana Company of America Inc. will provide management services that assist legal businesses to cultivate, sell, and distribute hemp and marijuana based products within the legal guidelines of individual states and international markets. hempSMART products are derived from Hemp and contain than a .3% THC content.
For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
Harmoneous.com
agoracom.com/ir/MarijuanaCompanyofAmerica
OTTAWA, ONTARIO–(Oct. 7, 2016) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRP0F) is pleased to announce that, on October 5, 2016, the Company entered into a non-binding agreement for a draw-down equity facility of up to $2,000,0000. Each Offering will occur exclusively at the option of the Company, throughout the 18-month term of the agreement.
The agreement provides for equity private placement offerings, to be conducted between Tetra and Alumina Partners LLC (“Alumina Partners“), a New York-based private equity firm.
Pursuant to the terms of the Offerings, Alumina Partners will commit to purchase up to $2,000,0000 of units of the Company (the “Units”), consisting of one common share (the “Shares”) and one common share purchase warrant (the “Warrants”). The placement will be at a discount of 20% of the market price of the Shares. The exercise price of the Warrants will be at a 25% premium over the market price of the Shares. The closing of the transaction is anticipated later this month.
“We are very pleased to be entering into this agreement with Alumina Partners. The purpose of the Offerings is to provide the Company with working capital to fund various projects as deemed necessary by the Board of Directors of the Company“, commented Andre Rancourt, Interim Chief Executive Officer.
“Alumina is excited to continue investing in the Canadian regulated cannabis industry, and looks forward very much to seeing the kind of innovative applied biotherapeutics and endocannabinoid-mediated agents that have yet to be discovered or even imagined, and that pioneers like Tetra Bio-Pharma will take the lead in exploring,” said Adi Nahmani, Managing Member of Alumina Partners LLC.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Scientific Officer
514-220-9225
Tetra Bio-Pharma Inc.
Andre Audet
Executive Chairman
613-421-8402
Tetra Bio-Pharma Inc.
Ryan Brown
President, Grow Pros MMP
613-421-8402
If you’re looking to invest in the small cap medical marijuana space, then Cannabix Technologies has to be high on your research list. Â Why? Â Anticipated legalization across the USA and Canada is obviously going to lead to higher use … which is going to automatically increase the need for monitoring right through the roof.
Specifically, police departments and the courts are going to need a way to both detect and convict impaired drivers.  The same goes for hazardous and dangerous jobs that require employees and heavy equipment operators to be anything but impaired.  Unfortunately, traditional saliva and urine tests simply can’t cut it.  The world will need a detection device that is fast, accurate and can hold up in a court of law.
Cannabix Technologies is in the process of bringing its marijuana breathalyzer to market.  With the underlying technology under license from the University of Florida and with the device in development as we speak, demand has already inundated Cannabix according to its President, Kal Malhi. The Company is in the final stages of completing its “Beta 2.0” device and expects to have a pilot test ready device for scientific trials for later this fall. The trial testing would be conducted to prove the accuracy and sensitivity of the Cannabix Breathalyzer, and the results would be used to apply for a court accepted device certification by the Minister of Justice in Canada and the National Highway and Traffic Safety Authority in the U.S.
Rule #1 when investing in small caps is make sure the company is run by smart people.  Kal Malhi is a former RCMP officer, where he completed his duties in the drug enforcement and organized crime divisions. He’s not only smart, he’s also been in the fight. Add on the fact he is the President of BullRun Capital and you have the prototype of Small Cap 2.0, the next generation of Canadian small cap companies that will be built for the long term, not to flip 5 cent paper.  Kal is the real deal.
BullRun has raising capital for various projects totaling in excess of $100 million dollars since 2008. Kal has specialized in working with academia, advances in technology and funded academic research that has potential for commercialization thru private and public companies.
Cannabix Technologies has the strong potential of creating both great shareholder value and societal benefits for years to come. I personally consider their product critically needed technology to keep our roads and families safe given the marijuana legislative easing that is taking place around North America.
Watch the interview and do your DD. As I’ve said before, we are officially in Weed 2.0 where you can bet on the long term development of real marijuana companies for decades to come. Just as Web 2.0 dwarfed the original dot-com bubble, Weed 2.0 is going to dwarf the original marijuana bubble. Do your research and make your investments.